Somatostatin Analog Therapy in Small Cell Lung Cancer

Semin Nucl Med. 2016 May;46(3):239-42. doi: 10.1053/j.semnuclmed.2015.12.004.

Abstract

Chemotherapy represents the cornerstone of treatment for patients with small cell lung cancer (SCLC); however, standard therapy has reached a plateau in improving patient survival with overall disappointing results. The demonstration that SCLC expresses neuroendocrine markers, such as somatostatin (SST) receptors, has led to use SST analogs or radiolabeled SST analogs in the treatment of SCLC patients. In the current review, we would focus on the possible role of SST analogs in SCLC.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / therapy*
  • Receptors, Somatostatin / metabolism
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / metabolism
  • Small Cell Lung Carcinoma / radiotherapy
  • Small Cell Lung Carcinoma / therapy*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / metabolism
  • Somatostatin / therapeutic use*

Substances

  • Receptors, Somatostatin
  • Somatostatin